Carvedilol Tablet, Film Coated
Product Images NDC 71335-2033

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Carvedilol (NDC 71335-2033). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1. Survival Analysis For Copernicus (intent-to-treat) (Carvedilol Tab Usp Figure1)

A line graph depicting percentage mortality over a period of up to 24 months. It compares two lines labeled 'Placebo' and 'Carvedilol,' showing lower mortality for Carvedilol. The graph includes a p-value of 0.0014 indicating statistical comparison between the two groups.*

FDA Label Image

Figure 2. Effects On Mortality For Subgroups In Copernicus (Carvedilol Tab Usp Figure2)

A forest plot chart illustrating the hazard ratios with confidence intervals across various patient subgroups, including demographics such as gender and age, clinical conditions like diabetes and ischemic status, heart rate and systolic blood pressure categories, and medication use including spironolactone. The chart compares these variables to assess risk across all patients.*

FDA Label Image

Figure 3. Survival Analysis For Capricorn (intent-to-treat) (Carvedilol Tab Usp Figure3)

A line graph depicting percent mortality over 24 months comparing two groups labeled "Placebo" and "Carvedilol." The y-axis represents percent mortality from 0 to 30%, and the x-axis represents time in months from 0 to 24. The graph shows lower mortality for the Carvedilol group compared to the Placebo group, with a p-value of 0.03 indicated on the chart.*

FDA Label Image

Figure 4. Effects On Mortality For Subgroups In Capricorn (Carvedilol Tab Usp Figure4)

A forest plot showing hazard ratios for various patient subgroups including age, sex, timing post-myocardial infarction, prior beta-blocker use, Killip class, thrombolytic therapy, PTCA treatment, congestive heart failure status, diuretic use during MI, angina presence, hypertension status, diabetes status, heart rate, and systolic blood pressure. The plot compares hazard ratios with confidence intervals for these groups, with a vertical reference line at 1.0.*

FDA Label Image

Carvedilol Chemical Structure (Carvedilol Tab Usp Structure)

Chemical structure of carvedilol, showing its molecular backbone and functional groups, as used in the medication carvedilol tablets.*

FDA Label Image

Label (Lbl713352033)

The label for Carvedilol 6.25 mg film-coated tablets, packaged by Bryant Ranch Prepack in Burbank, CA. The label notes that it is comparable to Coreg 6.25 mg tablets and lists Rubicon Research Private Limited as the manufacturer. The label indicates a package size of 30 tablets, includes storage instructions at room temperature (20°-25°C), and specifies 'RX Only'. The label also shows a barcode and an NDC number 71335-2033-1.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.